Navigation Links
Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
Date:4/21/2009

SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN), a San Diego-based biotechnology research and development company, announced today that its Board of Directors has declared a stock dividend to common and preferred shareholders of record as of May 5th, 2009 to be paid to shareholders on or about May 15th, 2009.

Eligible registered Common shareholders will be entitled to receive one share of Series B Preferred Stock for every 50 shares of Bio-Matrix Scientific Group, Inc. Common Stock owned as of the Record Date. Eligible registered Preferred shareholders will be entitled to receive one share of Series B Preferred Stock for every 50 shares of Bio-Matrix Scientific Group, Inc. Preferred Stock owned as of the Record Date.

Each holder of Series B Preferred Stock shall be entitled to two votes per share on all matters submitted to the stockholders.

The Preferred Share dividends will only be issued in the name of the beneficial owner of the Bio-Matrix Scientific Group Common and Preferred Stock and no dividend shares will be issued in the name of a broker dealer to disseminate to its clients.

Eligible Common shareholders whose Common shares of Bio-Matrix Scientific Group, Inc. are held in a brokerage account ("Street Name") must contact the brokerage firm holding their account to ensure that the dividend is processed correctly. Currently, no Preferred Shares are held in Street Name.

Broker Dealers holding Common shares in Street Name on behalf of clients shall be required to produce lists of Common shareholders designated by such Broker-Dealers as beneficial owners of the Company's Common stock as of the Record Date. Any lists provided by Broker Dealers must reconcile with records on file with the Depository Trust and Clearance Corporation (DTC) before the dividend may be paid by the Company.

Bio-Matrix also announced today the execution of a Separation and Distribution Agreement with the Company's wholly-owned subsidiary, Entest Biomedical, Inc. ("Entest") whereby the Company has agreed to spinoff the pro rata to the holders of its common and preferred stock 100% of the share capital of Entest.

"This division between Bio-Matrix and Entest will allow each company to focus on its business model," stated David Koos, Bio-Matrix's Chairman and CEO. "Bio-Matrix will be involved with the cryopreservation of adult stem cells and related specimens and pursue joint ventures with a variety of strategic partners at our 15,000 sq. ft. research laboratory facility in San Diego. Entest will strictly focus on research and development in the areas of diabetes regenerative medicine and medical devices. On October 23rd, 2008, Entest was granted an exclusive license by the University of California at Los Angeles to develop and market new gestational diabetes screening products based on UCLA's proprietary intellectual property. In addition, Bio-Matrix has granted to Entest all intellectual property related to the Company's 192 disposable medical instruments."

About Bio-Matrix Scientific Group Inc.:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, California with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Disclaimer:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
2. Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That Positive Cash Flow Is Possible in 09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview
3. Bio-Matrix Scientific Group, Inc. Gets Updated Stock Recommendation By KonLin Investment Letter
4. Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
5. Bio-Matrix Scientific Group Featured as Stock Pick in Oakleys Column on WallStreetCorner.com
6. Bio-Matrix Scientific Group Announces New Hires to Management Team
7. E&K Scientific Announces New Accuflow Product Line
8. Boston Scientific Announces First Quarter Special Items
9. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
10. Paul Keim Appointed to febits Scientific Advisory Board
11. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. ... marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The ... facilities during periods of rest. A lightweight, non-invasive monitor is placed on the ...
(Date:2/23/2017)... 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company ... announced that Linda Marbán, Ph.D, president and chief executive officer, ... Cowen and Company 37th Annual Health Care ... Boston, MA 29th Annual ... (12:00 pm ET) Dana Point, CA ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... acquired Kendall Research Systems, LLC (KRS) clinical development program. KRS is ... interface technology for research and clinical applications. The terms of the transaction were ...
(Date:2/22/2017)... ON (PRWEB) , ... February 22, 2017 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced it ... validate the ProMIS approach.” This is one of a series of commentaries from ...
Breaking Biology Technology:
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Biometrics Market 2017-2021" report to their offering. ... The global voice recognition biometrics ... 2017-2021. The report covers the present scenario and ... 2017-2021. To calculate the market size, the report considers the revenue ...
(Date:1/19/2017)... SANTA CLARA, Calif. , Jan. 19, 2017 ... Valley company enhancing user experience and security for ... provider of next-generation payment processing systems and cybersecurity ... assist more banks, enterprises and financial institutions worldwide ... As part of the end-to-end secure user authentication ...
Breaking Biology News(10 mins):